Equities research analysts expect Cardlytics Inc (NASDAQ:CDLX) to announce ($0.40) earnings per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Cardlytics’ earnings. The highest EPS estimate is ($0.32) and the lowest is ($0.54). Cardlytics posted earnings of ($0.35) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 14.3%. The company is expected to announce its next quarterly earnings results on Thursday, May 9th.
According to Zacks, analysts expect that Cardlytics will report full year earnings of ($0.87) per share for the current fiscal year, with EPS estimates ranging from ($1.11) to ($0.76). For the next financial year, analysts expect that the company will post earnings of $0.06 per share, with EPS estimates ranging from ($0.61) to $0.40. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Cardlytics.
Cardlytics (NASDAQ:CDLX) last posted its earnings results on Tuesday, March 5th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.11). Cardlytics had a negative net margin of 35.20% and a negative return on equity of 92.07%. The firm had revenue of $47.82 million during the quarter, compared to the consensus estimate of $45.32 million.
In related news, insider Kirk Somers sold 2,591 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $15.67, for a total value of $40,600.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO David Thomas Evans sold 2,634 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $15.42, for a total transaction of $40,616.28. The disclosure for this sale can be found here. Insiders sold a total of 22,087 shares of company stock valued at $348,050 in the last 90 days.
A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its position in Cardlytics by 0.4% in the 4th quarter. BlackRock Inc. now owns 422,718 shares of the company’s stock worth $4,578,000 after purchasing an additional 1,610 shares during the last quarter. Bank of America Corp DE raised its position in Cardlytics by 0.9% in the 4th quarter. Bank of America Corp DE now owns 270,025 shares of the company’s stock worth $2,924,000 after purchasing an additional 2,471 shares during the last quarter. Wells Fargo & Company MN raised its position in Cardlytics by 72.4% in the 3rd quarter. Wells Fargo & Company MN now owns 8,004 shares of the company’s stock worth $201,000 after purchasing an additional 3,361 shares during the last quarter. Bank of New York Mellon Corp raised its position in Cardlytics by 22.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,029 shares of the company’s stock worth $477,000 after purchasing an additional 3,476 shares during the last quarter. Finally, New York State Common Retirement Fund grew its holdings in Cardlytics by 80.0% during the 4th quarter. New York State Common Retirement Fund now owns 9,000 shares of the company’s stock worth $97,000 after acquiring an additional 4,000 shares during the period. Hedge funds and other institutional investors own 80.89% of the company’s stock.
Shares of NASDAQ:CDLX traded down $0.14 during trading on Friday, reaching $14.75. The stock had a trading volume of 163,215 shares, compared to its average volume of 185,315. Cardlytics has a 52 week low of $9.80 and a 52 week high of $28.29. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.90. The stock has a market capitalization of $298.89 million, a P/E ratio of -6.89 and a beta of 3.62.
Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
See Also: How to interpret the current ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.